Novonesis (formerly Novozymes) Strategy and Business Model

Executive Overview

Novonesis, the biosolutions company created when Novozymes combined with Chr. Hansen in January 2024, sits at the intersection of industrial biotechnology, food ingredients, and microbial solutions. Headquartered in Bagsværd, Denmark, the company develops enzymes, microbial cultures, probiotics, and related biological ingredients that help customers improve yield, taste, preservation, health outcomes, and resource efficiency. Its products are used by detergent makers, food and beverage producers, dietary supplement companies, feed manufacturers, biofuel plants, and agricultural customers. The business has deep historical roots: Chr. Hansen dates to 1874, Novo’s industrial-biotechnology lineage to 1925, and Novozymes itself was spun out from Novo Nordisk in 2000 before becoming part of Novonesis in 2024.

What makes Novonesis strategically distinctive is not one product line but a repeatable platform: identify or improve useful microbes and enzymes, manufacture them at scale through fermentation, and embed them in customer formulations and industrial processes. That gives the company exposure to both defensive categories such as food and household care and growth categories such as human health, animal health, agricultural biologicals, and industrial decarbonization. For FY2024, Novonesis reported revenue of about DKK 30 billion, roughly EUR 4 billion.

Novonesis at a Glance

Logo
Common name	Novonesis
Full legal name	Novonesis A/S (formerly Novozymes A/S)
Headquarters	Bagsværd, Denmark
Ownership	Public company; anchor shareholder Novo Holdings A/S through the inherited dual-class structure, with the remaining shares broadly held by institutional and retail investors
Ticker	NSIS B
Exchange	CPH - Nasdaq Copenhagen
Market Cap	#N/A
Revenue (FY2024)	$28.00B
Founding / major historical milestones	Roots in 1874 (Chr. Hansen) and 1925 (Novo); Novozymes spun out from Novo Nordisk in 2000; combination with Chr. Hansen closed in January 2024 and the company was renamed Novonesis
Industry or industries	Industrial biotechnology, food ingredients, microbial solutions, biosolutions, agricultural biologicals
Key products or services	Enzymes, microbial cultures, probiotics, functional proteins, feed solutions, agricultural biologicals, bioenergy and industrial biosolutions
Geographic footprint	Global, with major operations across Europe, North America, Asia-Pacific, and Latin America
Business segments as officially reported	As of FY2024, Novonesis discussed the portfolio through broad biosolutions areas including Food & Health Biosolutions, Planetary Health Biosolutions, and Agriculture, Energy & Tech
Company website	https://www.novonesis.com/

1. What Is the Strategy of Novonesis?

As of FY2024, Novonesis’s public strategy is best understood as building a scaled biosolutions platform after the merger of Novozymes and Chr. Hansen. The company is trying to win where biology can replace or improve conventional chemistry, additives, or process steps, and where customers will pay for measurable performance, regulatory reliability, and sustainability benefits.

1. 1a. What is the winning aspiration of Novonesis?

   Novonesis’s winning aspiration is to be the leading biosolutions partner for customers trying to make food, health, and industrial systems more productive and more sustainable. In practical terms, winning means becoming the default choice when a customer needs an enzyme, culture, probiotic, or other microbial solution that improves yield, reduces inputs, extends shelf life, supports health claims, or lowers environmental impact. After the January 2024 combination, management also framed winning in portfolio terms: one company with a broader biological toolbox, deeper customer access, and a larger innovation engine than either legacy business had on its own. Public merger materials also pointed to revenue and cost synergy targets; those are management targets, not completed facts.

2. 1b. Where does Novonesis play?

   Novonesis plays in business-to-business biosolutions, not in consumer packaged goods. Its chosen fields are end markets where biology can be embedded in customer formulations or processes: food and beverages, human health, household care, agriculture, animal health and nutrition, bioenergy, grain processing, and selected industrial applications. Geographically, it plays globally, with a particular emphasis on multinational customers that value consistent quality, regulatory support, and technical service across regions. Just as important, it does not try to be everything in life sciences; it is focused on scalable biological ingredients and process solutions rather than broad pharmaceuticals or commodity chemicals.

3. 1c. How does Novonesis plan to win?

   Novonesis plans to win through differentiated biology, application know-how, and scale manufacturing. Its value proposition is typically that a relatively small amount of a biological input can create a meaningful customer benefit: better cleaning at lower temperatures, more efficient ethanol conversion, better dairy fermentation, longer shelf life, lower feed conversion costs, or improved probiotic functionality. The post-merger strategy strengthens this because the combined company can offer more complete solution sets. For example, it can approach a food producer with both cultures and enzymes, or approach agricultural and feed customers with broader microbial capabilities. That combination increases share of wallet and raises switching costs.

4. 1d. What capabilities must Novonesis have in place?

   To execute this strategy, Novonesis needs a tight set of capabilities: microbial and enzyme discovery, fermentation scale-up, quality-controlled manufacturing, formulation and application science, regulatory documentation, global key-account coverage, and a supply chain that can deliver sensitive biological products consistently. It also needs integration capability after the 2024 merger, because a meaningful part of the strategy depends on combining legacy product portfolios, sales teams, systems, and manufacturing footprints without disrupting service.

5. 1e. What management systems does Novonesis require?

   Novonesis needs management systems that link science, manufacturing, and commercial execution. That includes stage-gated innovation processes, portfolio allocation across end markets, plant-yield and quality metrics, customer-specific technical service workflows, and post-merger synergy tracking. It also needs capital-allocation discipline because fermentation assets, application labs, and regulatory work all require sustained investment. Finally, because many customers buy Novonesis products for measurable sustainability or productivity outcomes, the company needs robust systems for documentation, claims support, and performance monitoring.

2. What Are the Current Strategic Initiatives of Novonesis?

As of FY2024, Novonesis’s strategic agenda is shaped by one dominant fact: the company is integrating two bioscience businesses into one platform while trying to accelerate growth. The current initiatives are therefore both offensive and operational.

• Integrate Novozymes and Chr. Hansen into one operating company. Since the combination closed in January 2024, Novonesis has been aligning commercial teams, leadership structures, functional processes, and systems. This is not merely administrative. The merger thesis depends on combining portfolios, customer coverage, procurement, manufacturing, and shared support functions.
• Capture cross-selling and solution-bundling opportunities. A key post-merger initiative is to use the combined product set to sell more deeply into existing accounts. In food and health, that can mean pairing cultures, enzymes, and probiotics; in agriculture and animal health, it means a broader microbial toolkit; in industrial applications, it means using biology to improve process economics and sustainability metrics.
• Expand higher-growth health and agriculture platforms. Human health biotics, animal health, and agricultural biologicals appear to be strategically important growth areas because they offer attractive long-term demand and fit the company’s biology capabilities. These categories typically require more scientific validation and regulatory work, but they can also be stickier and more differentiated.
• Support customer reformulation and decarbonization agendas. Novonesis is positioned where customers are trying to reduce salt, sugar, waste, energy use, water use, or chemical intensity. That makes food reformulation, low-temperature cleaning, biofuel yield optimization, and biological alternatives in agriculture important application priorities.
• Improve productivity in manufacturing and procurement. Because the company runs a global fermentation and biological production network, plant utilization, batch yields, utilities, raw materials, and service reliability all matter. Integration gives Novonesis an opportunity to rationalize footprint complexity and improve operating leverage over time.
• Keep the innovation engine full while simplifying the portfolio. Novonesis has to refresh its pipeline continuously, but it also has to avoid excessive complexity across stock-keeping units, formulations, and legacy platforms. The current strategy therefore appears to combine innovation spending with selective simplification.

3. What Is the Business Model of Novonesis?

What customers actually buy

Customers buy biological performance. The physical product may be an enzyme, a microbial culture, a probiotic, or another ingredient, but the economic purchase is usually an outcome: better process efficiency, cleaner labels, improved taste, longer shelf life, better crop or feed performance, higher yield, or lower energy and chemical consumption.

Recurring versus one-time revenue

Novonesis is primarily a repeat-purchase business. Once a customer has validated a biosolution inside a production process or formulation, purchases often recur for long periods because requalification can be costly and risky. Revenue is therefore more repeat-driven than one-time. New product introductions and reformulation wins matter, but they usually convert into ongoing supply rather than project revenue.

How pricing power works

Pricing power comes from value delivered, not from commodity volume. In many applications, Novonesis products are a small part of the customer’s total cost but a meaningful driver of performance. That can create pricing resilience when efficacy is proven and service is reliable. Pricing power is still bounded by customer procurement discipline, competing biological or chemical alternatives, and the fact that some large global customers have real buying leverage.

Why the business mix matters

Mix matters because not all biosolutions have the same economics. Food and health applications can be attractive because of differentiation, stickiness, and scientific barriers. Household care and certain industrial applications can offer scale and recurring demand. Agriculture and bioenergy can bring growth but may also be more exposed to seasonal or commodity-linked conditions. The combined portfolio matters because it smooths cyclicality and broadens customer relevance.

What drives margins and cash generation

Gross margin is heavily influenced by product mix, fermentation yields, plant utilization, raw-material costs, utilities, and quality performance. Operating margin depends on how efficiently Novonesis converts its large scientific, manufacturing, and commercial infrastructure into revenue growth. Cash generation depends on earnings quality, working-capital discipline, and capital expenditure on fermentation capacity, process upgrades, and integration projects. The revenue model is best described as recurring B2B product sales under supply relationships, supported by technical service and application development rather than subscriptions or licensing-heavy economics.

4. What Products and Services Does Novonesis Sell?

Novonesis sells a broad set of biological ingredients and process solutions. The portfolio is wide, but the strategic core remains enzymes, cultures, and microbial solutions that become embedded in customers’ workflows.

Legacy Novozymes categories such as detergent enzymes and industrial enzymes remain economically important, while the merger makes food, health, and microbial cultures materially more central to the portfolio than they were before 2024.

5. What Are the Key Competitors or Peers of Novonesis?

No single competitor matches Novonesis across every enzyme, culture, probiotic, and agricultural biological category. Competition is portfolio-dependent, so the closest peer set is best understood as a mix of direct rivals in specific verticals and broader bioscience comparables.

Substitutes also matter. In many applications, Novonesis competes not only with other biosolutions suppliers but with traditional chemical additives, conventional preservatives, process changes, or in-house customer workarounds.

6. What Is the Marketing Strategy of Novonesis?

Novonesis uses a science-led, business-to-business marketing model. Its marketing is less about mass brand advertising and more about demonstrating that a biological solution works reliably in a customer’s specific application. That means data, pilot results, regulatory support, sustainability documentation, and application expertise are central to the message.

• Account-based marketing: Large multinational customers often require tailored value propositions by category, region, and formulation.
• Application marketing: Novonesis has to show how a product performs in a real customer use case, such as dairy fermentation, laundry performance, ethanol yield, or feed conversion.
• Channel and trade marketing: In fragmented markets and some agricultural categories, distributors and local partners help educate customers and support adoption.
• Thought leadership around biosolutions: The company markets the broader idea that biology can improve economics and sustainability at the same time.

Marketing is an important support capability, but it does not appear to be the main source of competitive advantage. The deeper differentiators are scientific credibility, technical sales support, regulatory know-how, and long customer validation cycles that favor trusted suppliers.

7. What Are the Key Customer Segments of Novonesis?

Novonesis serves a diversified set of B2B customer groups, which is one reason the combined company is less dependent on any single end market than a pure-play industrial enzyme business or a pure-play food culture business would be.

• Food and beverage manufacturers: Dairy, baking, beverage, protein, and other food producers using cultures, enzymes, and preservation-related biosolutions.
• Human health customers: Supplement companies, health-focused brands, and other customers using probiotic and related biotic ingredients.
• Household products companies: Large detergent and cleaning-product manufacturers that use enzymes to improve efficacy and support lower-temperature washing.
• Animal nutrition and livestock customers: Feed producers, integrators, and related agricultural channels using feed enzymes and microbial solutions.
• Agricultural customers: Customers seeking biological inputs or microbial support for crop productivity and sustainability.
• Bioenergy and industrial processors: Ethanol producers and other industrial customers seeking process efficiency and higher conversion yields.

The customer base is broad, but some categories, especially global food and household-care accounts, can be commercially significant because of their scale and the multi-country nature of supply relationships.

8. What Is the Sales Model of Novonesis?

Novonesis sells primarily through direct B2B relationships supported by technical specialists. This is not a high-volume e-commerce model. It is a consultative sales model in which product qualification, process understanding, and regulatory documentation matter as much as price.

• Direct global accounts: Large multinational food, household-care, and industrial customers are typically covered directly by Novonesis key-account teams.
• Regional and local direct sales: Mid-sized accounts are often served by regional sales teams backed by application scientists.
• Distributors and partners: In more fragmented markets and selected agricultural channels, Novonesis uses intermediaries to extend reach.
• Technical-service overlay: Sales is closely linked to labs, application experts, and regulatory support because adoption often requires testing and validation.

This channel structure affects strategy in several ways. It improves customer intimacy and stickiness, supports value-based pricing, and creates natural opportunities for cross-selling after the merger. It also creates integration work: harmonizing customer coverage, incentive systems, distributor relationships, and CRM processes is a meaningful post-merger task.

9. In What Geographies Does Novonesis Operate?

Novonesis operates globally. Its customers are spread across Europe, North America, Asia-Pacific, Latin America, and other regions, and its operating footprint reflects the need to serve both multinational accounts and local market requirements.

The company’s headquarters is in Bagsværd, Denmark. Denmark remains a major center for leadership, research, and production. The broader manufacturing and R&D footprint also includes important operations in the United States and additional sites and capabilities across countries such as France, Germany, China, India, Brazil, and Argentina. The exact weight of each site changes over time as the combined company integrates legacy Novozymes and legacy Chr. Hansen assets.

Geographically, Novonesis is diversified rather than concentrated in one country, but Europe and North America remain especially important because of installed operations, major customer relationships, and scientific infrastructure.

10. Who Are the Owners of Novonesis?

Novonesis is a publicly listed company. As of 2024, Novo Holdings A/S remained the anchor shareholder through the dual-class ownership structure inherited from Novozymes, giving it outsized influence relative to ordinary public shareholders. The publicly traded B shares are otherwise broadly held by institutional investors and retail shareholders. Ownership percentages beyond that are time-sensitive and should be checked against the latest shareholder disclosures.

11. How Is Novonesis Organized?

At a practical level, Novonesis is organized as one integrated biosolutions company with a shared science-and-manufacturing backbone and market-facing commercial groups layered on top. The most important distinction is between how the company is run operationally and how investors think about the portfolio.

• Market-facing business areas: The company discusses broad biosolutions domains such as food and health, planetary or industrial applications, and agriculture-related activities.
• Regional commercial execution: Sales and customer support are necessarily regional because regulation, application needs, and channel structures vary by market.
• Shared scientific and operational platforms: Discovery, fermentation, manufacturing, procurement, quality, and regulatory capabilities support multiple end markets.
• Corporate integration layer: Since the 2024 merger, management also has to unify systems, people processes, and capital allocation across the legacy organizations.

The result is not a loose holding-company model. It is closer to a platform company where common capabilities in biology, fermentation, and customer applications are reused across multiple end markets.

12. How Does Novonesis Operate?

Novonesis operates by turning biological insight into repeatable industrial output. Day to day, that means a chain of activities that links science to commercial supply.

1. Discover and improve strains, enzymes, and formulations. Scientists identify promising microbes or enzymes and optimize them for specific customer outcomes.
2. Scale them through fermentation and downstream processing. Biological products then have to be produced reliably at industrial scale, often through complex fermentation, separation, drying, and formulation processes.
3. Validate performance in customer applications. Application teams test how solutions perform in real use cases such as dairy, detergents, feed, ethanol, or crop support.
4. Manage quality and regulatory requirements. Consistency, traceability, and documentation matter because many products are used in food, health, or tightly controlled industrial settings.
5. Supply and support the customer over time. The company then has to deliver product reliably and help the customer optimize use, troubleshoot issues, and transition to newer generations of products.

Operational complexity comes from long qualification cycles, biological manufacturing variability, plant utilization, and the need to coordinate a merged manufacturing and commercial footprint. In this business, service failures can jeopardize long customer relationships, so reliability matters as much as innovation.

13. What Are the Growth Opportunities for Novonesis?

Novonesis has several plausible growth opportunities, many of them directly tied to the 2024 combination.

• Cross-selling within the combined customer base: This is the clearest near- to medium-term opportunity. The merger broadens what the company can sell into each account.
• Food and health expansion: Human health biotics, food cultures, and enzyme-enabled reformulation are attractive because they benefit from health, convenience, and clean-label trends.
• Agricultural biologicals and animal health: Customers are looking for productivity gains with lower environmental impact, which plays to microbial solutions.
• Industrial decarbonization and resource efficiency: Enzymes and microbes can reduce energy, waste, and chemical intensity in household care and industrial processing.
• Emerging-market penetration: Food, feed, and agricultural productivity needs remain significant in faster-growing markets.
• Selective M&A and partnerships: The company now has a broader platform that could support targeted capability additions, especially in health and applied biology.

The main constraints are execution and timing. Customer adoption can be slow, regulation can delay commercialization, agricultural markets can be uneven, and the company still has to integrate systems and organizations after the merger. Fermentation capacity, product complexity, and internal prioritization can also limit how quickly opportunities turn into revenue.

14. What Is the History of Novonesis?

Novonesis is a new corporate name built on old scientific lineages. One side of the company comes from Chr. Hansen, founded in 1874, which built expertise in cultures, enzymes, and health-related microbial solutions. The other side comes from Novo’s industrial-biotechnology heritage dating to 1925. Novozymes itself became a standalone listed company in 2000 through a spin-off from Novo Nordisk.

For much of its independent history, Novozymes was best known as a global leader in industrial enzymes, with strong positions in household care, food and beverage processing, bioenergy, and agriculture. Chr. Hansen built a complementary position in cultures, probiotics, and microbial solutions used in food, health, and agriculture.

In December 2022, Novozymes and Chr. Hansen announced plans to combine. The transaction closed on January 29, 2024, after regulatory approvals, and the combined company adopted the Novonesis name. That deal is the defining event in the company’s recent history because it changed Novozymes from a leading enzyme specialist into a broader biosolutions platform.

15. What Are the Key Suppliers to Novonesis?

Suppliers matter because Novonesis depends on a stable flow of biological feedstocks, utilities, process inputs, packaging, and specialized equipment. Public disclosures do not usually emphasize a small set of named strategic suppliers, but several categories are clearly important.

• Fermentation feedstocks and nutrients: Sugars, carbohydrate sources, growth media, and other nutrient inputs for microbial production.
• Utilities and energy: Electricity, steam, water, and other utilities are material because fermentation and downstream processing are energy- and utility-intensive.
• Chemicals and processing aids: Inputs used in purification, formulation, sanitation, and quality-controlled manufacturing.
• Packaging and cold-chain materials: Especially important for products with stability or handling requirements.
• Process equipment and engineering partners: Fermenters, drying systems, automation, and plant-maintenance support are critical to uptime and yields.
• Logistics providers: Global transport, warehousing, and in some categories temperature-controlled handling matter to customer service.

Supplier structure matters strategically because raw-material inflation, utility costs, and equipment reliability can affect margins and service levels more quickly than in a pure software or low-asset business.

16. How Does the Supply Chain of Novonesis Function?

Novonesis has a biologics supply chain, not a simple buy-and-ship model. The supply chain begins with raw-material sourcing and production planning, then moves through fermentation, downstream processing, quality release, warehousing, and global distribution.

1. Sourcing: Secure feedstocks, nutrients, packaging, utilities, and process inputs.
2. Production planning: Match fermentation capacity and campaign schedules to demand across many stock-keeping units.
3. Manufacturing: Run fermentation and downstream processing with tight control over contamination risk, yields, and product consistency.
4. Inventory and fulfillment: Balance service levels with shelf-life and working-capital considerations.
5. Distribution and technical service: Deliver globally and support customers in implementation and troubleshooting.

Reliability is strategically important because many customers build Novonesis products into continuous production processes. Some categories, especially cultures and health-related products, can also impose stricter handling and quality requirements than typical bulk industrial chemicals.

17. What Are the Key Assets of Novonesis?

Novonesis is more asset-intensive than many specialty-ingredient peers because industrial biotechnology requires both physical manufacturing assets and scientific intangible assets.

• Fermentation and downstream processing plants: These are the core physical assets that allow the company to scale biology into commercial output.
• Culture and probiotic manufacturing capabilities: Specialized production, drying, formulation, and quality systems matter in food and health categories.
• R&D and application centers: Labs where strains are developed, products are tested, and customer applications are validated.
• Microbial strain libraries and enzyme know-how: These are critical intangible assets that underpin differentiation and product refresh.
• Regulatory dossiers, quality systems, and customer qualifications: These are often hard to replicate and create practical barriers to switching.
• Long-standing customer relationships: In this industry, installed positions inside customer formulations are economically valuable assets.

Asset intensity raises capital requirements but also creates barriers to entry. Competitors can copy a concept more easily than they can replicate a global, validated biology platform with scaled manufacturing and trusted customer positions.

18. What Is the Technology Strategy of Novonesis?

For Novonesis, technology means far more than information technology. The company’s technology strategy sits at the intersection of biology, fermentation engineering, process control, and data science. Its competitive edge depends on turning scientific discovery into reproducible industrial production faster and more efficiently than alternatives.

There are two layers to the strategy. The first is technology as part of the customer offering: enzyme engineering, microbial design, formulation science, and application technologies that improve customer outcomes. The second is technology as an internal enabler: fermentation process optimization, manufacturing automation, analytics, digital quality systems, and data platforms that improve yield, cycle time, and reliability.

The post-merger logic strengthens this technology strategy because the combined company has a broader biological toolbox and more end-market data. If integrated well, that should improve prioritization, customer solution design, and R&D productivity.

19. What Is the R&D Strategy of Novonesis?

R&D is central to Novonesis. This is not a business that can rely on a static catalog for long. Customers continually ask for better efficacy, cleaner labels, new health claims, lower cost-in-use, and lower environmental impact, so the company needs a steady pipeline of improved strains, enzymes, cultures, and formulations.

The R&D strategy appears to have four elements. First, maintain and refresh the core platforms in enzymes, cultures, and microbes. Second, prioritize application areas where scientific differentiation can support pricing and stickiness, especially health, food, and agriculture. Third, tie R&D closely to customer application work so that products are built for commercial adoption rather than laboratory novelty. Fourth, improve development productivity through data, platform reuse, and post-merger portfolio rationalization.

In Novonesis’s model, successful R&D is not only invention. It also includes scale-up, regulatory evidence, and customer validation. That makes the R&D system broader and more operational than the term sometimes implies.

20. What Is the Finance Strategy of Novonesis?

As of FY2024, Novonesis’s finance strategy appears oriented around disciplined integration, margin improvement, and preserving flexibility to invest. The merged company has a business mix that can produce strong cash generation, but it also requires sustained investment in science, manufacturing capacity, systems, and working capital.

• Capture merger synergies: A major part of the economic case rests on converting integration into lower costs and better commercial leverage over time.
• Reinvest in capacity and innovation: Fermentation assets, process improvements, and R&D remain essential to competitiveness.
• Protect cash conversion: Working capital, service levels, and inventory discipline are important in a global biological-products business.
• Maintain balance-sheet flexibility: The company benefits from having room for selective investments, resilience, and possible bolt-on deals.

Relative to more acquisitive industrial roll-ups, Novonesis appears financially conservative. The bigger challenge is not financial engineering; it is translating scientific scale and merger integration into sustained organic growth and operating leverage.

21. What Major Acquisitions Has Novonesis Made?

The defining transaction is the combination with Chr. Hansen. Announced in 2022 and completed on January 29, 2024, the deal transformed the old Novozymes into a broader biosolutions company with stronger positions in food cultures, health-related microbial solutions, and agricultural biology. Strategically, this was not just a scale acquisition. It was a portfolio-combination deal intended to join complementary scientific capabilities, customer relationships, and end markets.

Public merger materials emphasized both cost and revenue synergies. Those should be treated as management targets tied to the deal rationale, not as automatically delivered outcomes. The real test is execution: combining product portfolios, commercial organizations, manufacturing footprints, and R&D priorities without slowing growth.

More broadly, the company appears more selective than serial in M&A. The large transformational move has already happened; future deals are more likely to be bolt-ons that add technology, health capabilities, agricultural biology, or regional reach.

22. How Is Novonesis Using AI?

Publicly available information suggests that Novonesis uses data science and machine learning mainly as internal enablers rather than as a standalone AI product business. The most plausible live use cases are in enzyme and microbial discovery, strain selection, formulation work, process optimization, and analytics inside manufacturing and quality systems.

That distinction matters. Novonesis is not primarily selling AI to customers. It is using computational tools to improve how it discovers biological solutions, prioritizes experiments, and runs complex production systems. This fits the company well because its core challenge is finding high-performing biological candidates and scaling them efficiently.

Where AI becomes strategically important is at the interface of biology and data: narrowing search spaces in R&D, improving fermentation yields, accelerating technical documentation, and helping scientists reuse knowledge across the combined Novozymes and Chr. Hansen base. Public disclosures do not support treating AI as a separate revenue line; they support treating it as a productivity and innovation layer.

23. How Companies Like Novonesis Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of over 8,000 independent management consultants based in more than 50 countries. These consultants are alums of McKinsey, Bain, BCG, and other top consulting firms. Companies like Novonesis engage Umbrex when they need talent with the training these top global firms provide but do not need a full team with all the overhead. Umbrex has consultants across Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI.

For a company such as Novonesis, the most relevant independent-consultant projects are tightly linked to post-merger integration, growth acceleration, and operational excellence:

• Post-merger integration office support, including synergy tracking, milestone governance, and issue escalation across commercial, operations, and functions
• Cross-selling and key-account opportunity mapping between legacy Novozymes and legacy Chr. Hansen customer bases
• Pricing and value-selling redesign for food, health, household care, and industrial biosolutions portfolios
• Fermentation network and manufacturing-footprint optimization, including capacity, campaign planning, and plant-utilization analysis
• Strategic sourcing and procurement programs for feedstocks, utilities, packaging, and critical process inputs
• Growth strategy for agricultural biologicals, animal health, or human health biotics in priority geographies
• Salesforce and distributor model redesign, especially where regional channels differ by end market
• ERP, master-data, and commercial-reporting harmonization following the 2024 merger
• R&D portfolio prioritization and stage-gate redesign to improve innovation productivity across the combined company
• AI and analytics use-case design for scientific knowledge management, regulatory-document workflows, and manufacturing optimization